Cancer Immunology and Immunotherapy Center, Cancer Research Center, Saint Savas Cancer Hospital, 11522 Athens, Greece.
Department of Urology, Saint Savas Cancer Hospital, 11522 Athens, Greece.
Int J Mol Sci. 2023 Mar 22;24(6):5954. doi: 10.3390/ijms24065954.
HER-2/ is the human epidermal growth factor receptor 2, which is associated with the progression of prostate cancer (PCa). HER-2/-specific T cell immunity has been shown to predict immunologic and clinical responses in PCa patients treated with HER-2/ peptide vaccines. However, its prognostic role in PCa patients receiving conventional treatment is unknown, and this was addressed in this study. The densities of CD8+ T cells specific for the HER-2/ peptide in the peripheral blood of PCa patients under standard treatments were correlated with TGF-β/IL-8 levels and clinical outcomes. We demonstrated that PCa patients with high frequencies of HER-2/-specific CD8+ T lymphocytes had better progression-free survival (PFS) as compared with PCa patients with low frequencies. Increased frequencies of HER-2/-specific CD8+ T lymphocytes were also associated with lower levels of TGF-β and IL-8. Our data provide the first evidence of the predictive role of HER-2/-specific T cell immunity in PCa.
HER-2/是人表皮生长因子受体 2，与前列腺癌（PCa）的进展相关。已经证明，HER-2/肽疫苗治疗的 PCa 患者中，HER-2/-特异性 T 细胞免疫可预测免疫和临床反应。然而，其在接受常规治疗的 PCa 患者中的预后作用尚不清楚，本研究对此进行了探讨。本研究分析了标准治疗下 PCa 患者外周血中针对 HER-2/肽的 CD8+T 细胞的密度与 TGF-β/IL-8 水平和临床结局的相关性。我们发现，与低频 HER-2/-特异性 CD8+T 淋巴细胞的 PCa 患者相比，高频 HER-2/-特异性 CD8+T 淋巴细胞的 PCa 患者具有更好的无进展生存期（PFS）。HER-2/-特异性 CD8+T 淋巴细胞的频率增加也与 TGF-β和 IL-8 水平降低相关。本研究数据首次提供了 HER-2/-特异性 T 细胞免疫在 PCa 中的预测作用的证据。
